Skip to main content

Table 1 Patient characteristics

From: Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis

Characteristics Before propensity score matching After propensity score matching
CBDCA+PEM CBDCA+PTX p-value CBDCA+PEM CBDCA+PTX p-value
(n = 135) (n = 105)   (n = 94) (n = 94)  
n (%) n (%)   n (%) n (%)  
Sex Male 84 (62.2) 89 (84.8) < 0.001 78 (83.0) 78 (83.0) 1.000
Female 51 (37.8) 16 (15.2)   16 (17.0) 16 (17.0)  
Age, years < 65 56 (41.5) 46 (43.8) 0.793 37 (39.4) 43 (45.7) 0.461
≥65 79 (58.5) 59 (56.2)   57 (60.6) 51 (54.3)  
Motion sickness No 122 (90.4) 99 (94.3) 0.338 85 (90.4) 89 (94.7) 0.406
Yes 13 (9.6) 6 (5.7)   9 (9.6) 5 (5.3)  
Drinking habit No 78 (57.8) 52 (49.5) 0.240 45 (47.9) 45 (47.9) 1.000
Yes 57 (42.2) 53 (50.5)   49 (52.1) 49 (52.1)  
Number of antiemetics 2 95 (70.4) 91 (86.7) 0.003 80 (85.1) 80 (85.1) 1.000
3 40 (29.6) 14 (13.3)   14 (14.9) 14 (14.9)  
  1. CBDCA+PEM carboplatin+pemetrexed, CBDCA+PTX carboplatin+paclitaxel